Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Treatment of subclinical depression with a CBT program (DIAMOS) : Results of a prospective randomized, controlled study

Publication

Treatment of subclinical depression with a CBT program (DIAMOS) : Results of a prospective randomized, controlled study

Kulzer, Bernhard; Schmitt, Andreas; Reimer, Andre; u. a. (2017): Treatment of subclinical depression with a CBT program (DIAMOS) : Results of a prospective randomized, controlled study, in: Bamberg: opus, doi: 10.2337/db14-665-832.

Details

Faculty/Chair
Author
Schmitt, Andreas
Reimer, Andre
Haak, Thomas
Conference
ADA 74th Scientific Sessions, 13.-17. June 2014, San Francisco, California
Publisher Information
opus : Bamberg
Year of publication
2017
Pages
1
Source/Other editions
Ursprünglich in: Diabetes : the journal of the American Diabetes Association 63 (2014) Supplement 1, A170-A212
Year of first publication
2014
Language
English
Licence
DOI
URL
URN
Abstract

Depression without meeting the criteria of a major depression. However, elevated depressive symptoms are associated with a reduced quality of life, lower self-care activities, and a higher mortality. To target this large group of people, a diabetes-specific treatment program (DIAMOS) was developed and evaluated in a randomized controlled trial with a 12-month follow-up. DIAMOS is a group program based on cognitive-behavioral-therapy (CBT). It consists of 5 group sessions which lasts for 90 minutes each. 214 inpatients with subclinical depression were randomized either to DIAMOS or to a control group receiving diabetes education. Depression, diabetesrelated distress, and quality of life were assessed via questionnaires (CES-D, PAID, WHO-5 respectively). HbA1c was analyzed in a central laboratory.181 patients (age: 45±14 yrs.; 57% female; 63% Type 1 DM; diabetes duration 15±11 yrs.; 95% with insulin; 51% with late complications; HbA1c 8.8±1.7%; CES-D 23.3±8.1; PAID 39.5±18.4; WHO-5 8.9±4.5) were available at the 12-month follow-up (drop-out rate: 15%). Compared to the control group, patients treated with DIAMOS showed a significantly greater reduction of depressive symptoms (- 7.4 ± 11.4 vs. - 2.7 ± 11.7; p < .01), and diabetes-related distress (- 13.0 ± 18.9 vs. - 4.2 ± 16.9; p < .01), as well as a significantly greater improvement of quality of life (+ 4.5 ± 6.1 vs. + 2.5 ± 6.3; p = .03). HbA1c improvement was comparable in both groups. The results demonstrate that DIAMOS is an effective tool for the treatment of subclinical depression in people with diabetes. In addition, DIAMOS positively affects diabetes-related distress and quality of life. Interestingly, the reduction of depressive symptoms and distress was not associated with an improvement of glycemic control. DIAMOS proofs to be an innovative tool for routine care to improve the situation of people with diabetes and subclinical depression.

Peer Reviewed
yes
International Distribution
yes
Type
Conferenceobject
URI
Activation date
2017-01-26, 2017-01-26

Permalink: https://fis.uni-bamberg.de/handle/uniba/41473 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.